Innocell, recurrent epithelial ovarian cancer
Phase 1, City of Hope
An FDA-cleared study evaluating safety and immunogenicity. ClinicalTrials.gov NCT06366490.
View clinical studyInnocell™ / Personalized cellular immunotherapy
A broader view
of cancer.
Every tumor carries a different set of antigens. Innocell starts with the patient’s own tumor cells to preserve that breadth.
Discover the science01 / 04
A tumor’s own signature.
A patient’s tumor cells carry many different antigens. Those surface signals are the starting point for Innocell.
Patient-derived tumor cell · Surface antigens in gold
Drag to explore the cell. Choose a stage to follow the process.
Conceptual cellular illustration
Conceptual illustration · Not to scale. Innocell is investigational.
In clinical development
Phase 1 study at City of Hope
Innocell for recurrent
epithelial ovarian cancer
The tumor supplies the targets.
Solid tumors are heterogeneous: their cells can carry different antigens. Innocell keeps the patient’s broad tumor-antigen repertoire, rather than selecting a small set of targets.
Conceptual illustration · Not to scale
Personalized at the source
The patient’s tumor supplies the antigens. The approach preserves their breadth through the inactivation process.
Prepared without cell expansion
One tissue preparation can yield multiple doses. A turnaround of less than seven days is anticipated at commercial scale.
Innocell is investigational. Safety and immunogenicity are being evaluated in a Phase 1 study. The illustration explains the proposed mechanism; it does not depict clinical results.
Research and publicationsClinical development
Starting with recurrent ovarian cancer.
Innocell with bevacizumab, ovarian cancer
Phase 1b plannedA planned combination cohort in the ovarian cancer program.
Lung, colorectal, breast, melanoma
Preclinical developmentPotential expansion into additional solid tumors.
Canine cancer
Published case studyEarly translational work reported by Goodrich et al., J. Immunol. Res. (2020).
US patent 12,280,039 covers Innocell compositions. Innocell is an investigational therapy and is not approved for commercial use.
Built by people who have taken therapies to market.
Ray Goodrich, PhD
Co-founder, CEO and CSO; Director
Thomas Bogenrieder, MD, PhD
(Acting) Chief Medical Officer
Christopher J. Welsh
Director of Quality Assurance
Susan Yonemura, PhD
Director of Product Development
David Reinhold Brill, PhD
Director of Regulatory Affairs
Beth Crump
Director of Clinical Affairs
News and publications.
- Sara Sellers joins PhotonPharma from Colorado State University
Talk to us.
Connect with our team.
admin@photonpharma.netPhotonPharma, Inc., Research Innovation Center, 3185 Rampart Road, Fort Collins, CO 80523.
A note on recruitment scams
A note on recruitment scams. PhotonPharma has been made aware of employment scams misrepresenting our company. We do not use outside recruiters. Official correspondence comes only from @photonpharma.net addresses, and we would never request a payment or financial information during recruiting. To verify a contact, email admin@photonpharma.net. Report scams to the FTC at reportfraud.ftc.gov or the FBI at ic3.gov.